The Future of Perioperative Therapy for Urothelial Cancer and Challenging Cases in Prostate Cancer

The Future of Perioperative Therapy for Urothelial Cancer and Challenging Cases in Prostate Cancer

Introduction:

In recent years, significant advancements have been made in the field of urothelial cancer treatment. From the identification of critical urothelial cancer genes to the development of biomarker-driven therapies, the landscape of perioperative therapy is rapidly evolving. Additionally, challenging cases in prostate cancer continue to push the boundaries of medical science. In this article, we will explore the latest findings from the EAU 2020 conference on perioperative therapy for urothelial cancer and the ASCO GU 2020 conference on challenging cases in prostate cancer.

Perioperative Therapy for Urothelial Cancer:

One of the key takeaways from the EAU 2020 conference was the high prevalence of mutations in urothelial carcinoma. This suggests that all patients with metastatic urothelial carcinoma should be offered testing. Identifying these mutations can help determine the most appropriate treatment plan for each individual. The most critical urothelial cancer genes identified thus far include MMR, FGFR, and DNA repair genes. Understanding the performance characteristics of new commercially available tests is essential for effective implementation.

Biomarker-driven therapy has emerged as a promising approach in urothelial cancer treatment. By analyzing the molecular characteristics of tumors, we can identify patients who are most likely to respond to specific therapies. In fact, research indicates that 69% of tumors harbor potential therapeutic targets. One potential avenue for therapy is the use of PARP inhibitors, particularly in cases where DDR pathway alterations are present. Additionally, microsatellite instability, which is frequent in upper tract urothelial carcinoma, can guide treatment decisions.

It is worth noting that familial and hereditary urothelial carcinoma accounts for a significant portion of cases. Approximately 10% of cases are familial, while hereditary urothelial carcinoma makes up 15% of upper tract urothelial carcinomas and 5% of bladder urothelial carcinomas. These findings have important implications not only for the treatment of metastatic disease but also for the prevention and screening of family members.

Challenging Cases in Prostate Cancer:

At the ASCO GU 2020 conference, challenging cases in prostate cancer were discussed. One such case involved the use of PSMA PET/CT imaging in determining the need for salvage lymphadenectomy. Dr. Eggener suggested that salvage lymphadenectomy may be considered in patients who are low risk for further metastatic disease and in whom the surgery is technically feasible. Factors such as a favorable Gleason score may play a role in the decision-making process.

Connecting the Dots:

While the topics of perioperative therapy for urothelial cancer and challenging cases in prostate cancer may seem unrelated, there are common threads that can be drawn. Both fields emphasize the importance of personalized medicine and precision oncology. By identifying specific mutations in urothelial carcinoma, we can tailor treatments to individual patients, maximizing the chances of success. Similarly, in challenging cases of prostate cancer, advanced imaging techniques like PSMA PET/CT can help determine the most appropriate surgical interventions.

Actionable Advice:

1. Encourage testing: Given the high prevalence of mutations in urothelial carcinoma, it is crucial to offer testing to all patients with metastatic disease. Identifying these mutations can guide treatment decisions and improve patient outcomes.

2. Stay informed: Keep up-to-date with the latest developments in biomarker-driven therapy. Understanding the performance characteristics of new tests and potential therapeutic targets can greatly impact treatment decisions for urothelial carcinoma patients.

3. Consult multidisciplinary teams: In challenging cases of prostate cancer, it is essential to involve a multidisciplinary team in decision-making processes. Collaboration between urologists, oncologists, and radiologists can help determine the most appropriate treatment plan.

Conclusion:

The future of perioperative therapy for urothelial cancer is promising, with advancements in biomarker-driven therapy and the identification of critical urothelial cancer genes. Similarly, challenging cases in prostate cancer continue to push the boundaries of medical science, with advanced imaging techniques playing a crucial role. By incorporating personalized medicine and precision oncology, we can improve patient outcomes and revolutionize the field of urologic oncology.